Evidence map›Paper›PMID 38966544›Full record

ArticleFrontiers in pharmacology2024

Case report: a cataract induced by bleomycin in a patient with testicular cancer.

Wan Zhang, Yinghua Ji, Yufei Sun, Keya Zhi, Han Yang, Min Zhang, Ping Lu, Yana Zhang

Abstract readCase Reports
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wan ZhangDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yinghua JiDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yufei SunDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Keya ZhiDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Han YangDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Min ZhangDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Ping LuDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yana ZhangDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bleomycin is a glycopeptide antibiotic with outstanding anti-tumor effects. A major adverse effect of bleomycin is lung fibrosis. However, the development of cataracts as a severe adverse effect has not been reported. Case summary: Herein, we describe the first case of cataract induced by bleomycin therapy in a 22-year-old male with testicular cancer. After surgical intervention and following five successive chemotherapy cycles of the BEP regimen, including bleomycin, etoposide and cisplatin, the patient reported a gradual painless loss of vision, with substantial decline in visual ability, especially in the right eye. Following comprehensive eye examinations, a cataract was diagnosed. Eventually, the patient underwent phacoemulsification and received replacement of the intraocular lenses. Conclusion: Bleomycin can cause cataracts, which induces a significant loss of vision. Therefore, clinicians should observe early symptoms and properly adjust treatment to prevent aggravation of symptoms.

Indexed as

adverse effectsbleomycincataractchemotherapytesticular cancer

Identifiers

PMID38966544
PMCPMC11222336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.